证券代码:300463 证券简称:迈克生物 公告编号:2024-027 迈克生物股份有限公司 迈克生物股份有限公司（以下简称"迈克生物"或"公司"）《2023年年度报告》及其摘要将于 2024年4月25日在巨潮资讯网（http://www.cninfo.com.cn）披露。 为了让广大投资者进一步了解公司2023年年度经营业绩、发展战略情况，公司拟定于2024 年4月30日（星期二）15:00-17:00在价值在线举办2023年度业绩说明会，本次年度业绩说明会 将采用网络远程的方式举行，投资者可登陆价值在线（https://eseb.cn/1dVJpPy4cms）参与本次 年度业绩说明会。 出席本次说明会的人员有：公司总经理吴明建、财务总监尹珊、董事会秘书史炜、独立董 事傅代国、保荐代表人鄢坚。 为充分尊重投资者、提升交流的针对性，现就公司2023年度业绩说明会提前向投资者公开 征集问题，广泛听取投资者的意见和建议。投资者可于2024年4月30日（星期二）前访问 https://eseb.cn/1dVJpPy4cms或使用微信扫描下方小程序码，进入问题征集专题页面。公司将在 2023年度业绩说明会上，对投资者 ...

证券代码:300463 证券简称:迈克生物 公告编号:2024-036 迈克生物股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募集资金管理和使 用的监管要求》（证监会公告〔2022〕15号）《深圳证券交易所上市公司自律监管指引第2号— —创业板上市公司规范运作》以及《深圳证券交易所创业板上市公司自律监管指南第2号—— 公告格式》《深圳证券交易所创业板上市公司业务办理指南第6号——信息披露公告格式》的相 关规定，将迈克生物股份有限公司（以下简称"公司"）2023年度募集资金存放与实际使用情 况报告如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发行股票注册 的批复》（证监许可〔2021〕412 号）的核准，迈克生物股份有限公司（以下简称"公司"）本次 向特定对象发行人民币普通股（A 股）56,000,000 股，每股发行价格为 28.11 元/股，募集资 ...

Regional Revenue Breakdown - Northeast region revenue: 225,520,785.38 RMB, accounting for 7.79% of total revenue[1] - North China region revenue: 331,306,222.13 RMB, accounting for 11.44% of total revenue[1] - East China region revenue: 517,166,191.62 RMB, accounting for 17.86% of total revenue[1] - Central China region revenue: 226,862,637.73 RMB, accounting for 7.83% of total revenue[1] - South China region revenue: 182,913,613.90 RMB, accounting for 6.32% of total revenue[1] - Northwest region revenue: 219,220,451.56 RMB, accounting for 7.57% of total revenue[1] - Southwest region revenue: 1,090,898,703.75 RMB, accounting for 37.67% of total revenue[1] - Overseas region revenue: 101,880,905.95 RMB, accounting for 3.52% of total revenue[1] Sales Channels - Direct sales revenue: 1,056,481,998.80 RMB, accounting for 36.48% of total revenue[1] - Distribution sales revenue: 1,839,287,513.22 RMB, accounting for 63.52% of total revenue[1] Product Development and R&D - The company has established a "8+1" product technology platform, including biochemistry, immunity, blood cells, coagulation, urine, molecular, blood type, pathology, and rapid testing, with 512 registered certificates for self-developed in vitro diagnostic products[22] - In 2023, the company completed the development of 30 raw materials, including 19 antibodies, 6 antigens, and 5 chemical raw materials, with a self-sufficiency rate of core raw materials exceeding 50%[22] - The company added 64 new products during the reporting period, bringing the total number of registered products to 512[28] - The company completed 71 R&D projects in 2023, with 572 projects still in progress, and invested a total of 414.02 million yuan in R&D[40] - The company's R&D team consists of 1,172 personnel, with 577 focused on clinical testing and 595 on other diagnostic areas[40] - The company's R&D investment increased by 22.34% to 414 million yuan, with R&D personnel growing by 149 to 1,172, accounting for 34.86% of total employees[88] - The company obtained 64 new domestic product registrations in 2023, bringing the total to 512, including 485 reagents and 27 instruments[119] - The company launched the LABAS MIX fully automated laboratory intelligent assembly line, integrating ten functions such as automatic quality control detection and multi-mode sample input[119] - The company added 19 new reagent product registrations for its acridinium ester direct chemiluminescence technology platform, bringing the total to 102[119] Financial Performance - The company's revenue for the four quarters of 2023 were 676.4 million, 704.3 million, 734.4 million, and 780.7 million respectively[29] - The net profit attributable to shareholders for the four quarters of 2023 were 116.9 million, 58.0 million, 93.8 million, and 43.9 million respectively[29] - The net cash flow from operating activities for the four quarters of 2023 were 167.0 million, 242.7 million, 207.4 million, and 284.4 million respectively[29] - The company's revenue for the reporting period was 2.896 billion yuan, a year-on-year decrease of 19.75%, with net profit attributable to shareholders of 313 million yuan, a year-on-year decrease of 55.86%[61] - Total operating revenue for 2023 was RMB 2,895,769,512.02, a decrease of 19.75% compared to 2022[62] - Revenue from self-developed products accounted for 64.94% of total revenue, amounting to RMB 1,880,368,645.95, a decrease of 18.67% year-over-year[62] - Revenue from agent products was RMB 981,448,342.17, accounting for 33.89% of total revenue, a decrease of 21.87% compared to 2022[62] - The company's net profit was 212,756,122.56, compared to 368,913,140.91 in the previous period[108] - The company's total comprehensive income was 199,197,097.20, compared to 384,841,761.44 in the previous period[108] - Revenue for 2023 was 2,895.77 million yuan, a decrease of 19.75% compared to the previous year[144] Market Expansion and Distribution - The company's self-developed products cover over 8,000 medical institutions nationwide, with coverage rates of 24% in secondary hospitals and 50% in tertiary hospitals[35] - The company has established partnerships with 566 distributors, and its products are available in 118 countries and regions, with overseas markets becoming a key focus for expansion[35] - The company has invested in overseas market expansion, setting up 2 overseas platform companies, 1 overseas office, and 1 overseas transit warehouse, with products covering 118 countries and regions[50] - The company has a wide marketing service network, with 12 channel subsidiaries, 17 offices, and 622 sales personnel in the domestic market, serving over 8,000 terminal customers[59] Product Sales and Inventory - The company's autonomous products achieved sales revenue of 1.714 billion yuan, a year-on-year increase of 4.92%, with 4,016 large instruments and production lines shipped to the terminal market[58] - Sales of immunodiagnostic reagents reached RMB 952 million, an increase of 18.68% year-over-year[70] - Sales of biochemical reagents were RMB 577 million, an increase of 2.54% year-over-year[70] - Sales of molecular diagnostic reagents dropped significantly to RMB 7.0451 million, a decrease of 98.79% year-over-year[70] - Inventory balance decreased by 12.7% at the end of 2023 compared to the previous year[71] - Accounts receivable balance decreased by 14.48% at the end of 2023 compared to the previous year[71] - Revenue from in vitro diagnostic products decreased by 19.75% to 2,895,769,512.02 yuan, with a gross margin of 55.27%[73] - Sales volume of diagnostic reagents dropped by 44.47% to 3.3274 million boxes, while production volume decreased by 44.57% to 3.1403 million boxes[73] - Sales volume of diagnostic instruments (large type) increased by 4.43% to 3,462 units, with production volume rising by 18.82% to 3,555 units[73] - Sales volume of diagnostic assembly lines surged by 122.15% to 351 units, with production volume increasing by 107.03% to 383 units[73] - The company achieved a total of 4,016 units (lines) of large instruments and assembly lines delivered to the market, including 189 biochemical and immune assembly lines and 162 blood assembly lines[74] - The company's diagnostic assembly line inventory increased by 77.5% to 71 units, driven by the promotion of full laboratory automation assembly lines[89] Financial Position and Assets - The company's debt-to-asset ratio decreased to 18.57% by the end of the reporting period, a reduction of 1.49 percentage points compared to the previous year[42] - The company's financing costs decreased by 7% year-on-year, with short-term and long-term loan ratios adjusted to 29%[42] - Cash and cash equivalents at the end of the period increased to 811,362,294.43 yuan, up from 564,293,033.08 yuan at the beginning of the period[110] - Net cash flow from financing activities was -152,750,581.74 yuan, compared to 930,049,187.87 yuan in the previous period[110] - Total assets at the end of the period were 8,119,249,307.93 yuan, slightly down from 8,168,350,292.26 yuan at the beginning of the period[126] - Fixed assets increased to 2,186,644,511.57 yuan from 1,979,045,213.17 yuan[126] - Short-term borrowings decreased to 144,647,498.10 yuan from 248,075,777.91 yuan[126] - The company's total equity at the end of the period was 6,611.462 million yuan[137] - The company allocated 28 million yuan for surplus reserves[135] - The company distributed 286.635 million yuan to shareholders[135] - The company's capital reserve increased by 973,812.19 yuan[135] - The company's total assets at the end of the period were 6,384.825 million yuan[137] - Inventory increased to 531,716,615.34 from 511,178,091.88, reflecting a growth of 4.02%[151] - Total current assets decreased to 4,612,719,595.24 from 4,750,174,683.29, a decline of 2.89%[151] - Long-term equity investments decreased to 1,011,979,841.96 from 1,030,817,115.07, a reduction of 1.83%[151] - Fixed assets increased significantly to 1,090,901,724.56 from 643,509,759.96, a growth of 69.53%[151] - Development expenditure rose to 35,090,057.08 from 26,227,525.22, an increase of 33.79%[151] - Cash received from sales of goods and services increased to 1,750,685,765.23 from 1,577,681,416.05, a growth of 10.97%[156] - Net cash flow from operating activities surged to 852,137,792.51 from 479,718,443.09, an increase of 77.63%[156] - Cash outflow for investments decreased to 2,608,658,144.10 from 3,305,095,470.26, a reduction of 21.07%[156] - Cash received from tax refunds increased significantly to 67,558,608.47 from 3,573,372.16, a growth of 1790.47%[156] - Total assets increased to 7,106,384,593.18 from 6,809,623,435.59, a growth of 4.36%[151] Corporate Governance and Shareholders - The company has 20 wholly-owned or controlled subsidiaries, including 12 domestic trading companies and 2 overseas trading companies, with R&D functions distributed across Chengdu, Hangzhou, Beijing, and the US[35] - The company released 80 temporary announcements and completed 59 investor research sessions in 2023[100] - The company's board consists of 9 members, including 3 independent directors[103] - The total restricted shares at the end of the reporting period were 117,119,807[104] - The number of ordinary shareholders at the end of the reporting period was 39,869, up from 38,606 at the end of the previous month[115] - The China Construction Bank-Huabao CSI Medical ETF exited the top ten shareholders, while the China Construction Bank-GF Healthcare Equity Fund was newly added[131] Quality Management and Traceability - The company has established a comprehensive quality management system, including 100,000-level clean rooms for microbial testing and barcode management for full traceability of product quality[49] - The company has established a leading metrological traceability system in the industry, being the first Chinese enterprise representative in the JCTLM international metrological traceability system[54] Product Line and Strategy - The company's products include a wide range of diagnostic platforms, such as biochemistry, immunology, hematology, and molecular diagnostics, with integrated automation solutions[34] - The company has a complete product line strategy, covering biochemical, immunological, hematological, molecular diagnostics, POCT, pathology, and raw materials, making it one of the most comprehensive IVD companies in China[54] Cost Management and Supply Chain - The company focuses on cost management, optimizing supply chain procurement and increasing the self-production rate of raw materials to reduce production costs[46] Guarantees and Subsidiaries - The total approved guarantee amount for subsidiaries during the reporting period was 143,000[95] - The actual guarantee amount issued during the reporting period was 45,022.77[95] - The total approved guarantee amount for subsidiaries at the end of the reporting period was 93,000[98] - The actual guarantee balance for subsidiaries at the end of the reporting period was 6,522.77[98] Financial Assets and Liabilities - The company's financial liabilities are initially classified as either financial liabilities measured at fair value through profit or loss or financial liabilities measured at amortized cost[181] - Financial assets measured at amortized cost include interest calculated using the effective interest method during the holding period, which is recognized in current profit or loss[183] - Financial assets measured at fair value through other comprehensive income (equity instruments) are initially measured at fair value, with related transaction costs recognized in current profit or loss[184] - Financial liabilities measured at fair value through profit or loss are initially measured at fair value, with related transaction costs recognized in current profit or loss[184] - The company terminates recognition of existing financial liabilities when substantial modifications are made to the contract terms, and the modified financial liability is recognized as a new financial liability[186] - The company measures the loss allowance for receivables at an amount equal to the lifetime expected credit losses, regardless of whether they contain a significant financing component[187] - The company's financial assets are initially classified as financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income (debt instruments), or financial assets measured at fair value through profit or loss[193] - Financial assets measured at fair value through other comprehensive income (debt instruments) are initially measured at fair value, with related transaction costs included in the initial recognition amount[196] - Upon derecognition, the cumulative gain or loss previously recognized in other comprehensive income is reclassified from other comprehensive income to retained earnings[197] - The difference between the consideration paid and the carrying amount of the financial liability is recognized in current profit or loss upon derecognition[198] Acquisitions and Equity Transfers - The company transferred 100% equity of Xinjiang Mike for 10.3852 million yuan on August 8, 2023[146] - The company acquired 100% equity of Beijing Dawei Microorganism Technology Co., Ltd. in November 2020 and March 2022[146] - As of September 30, 2023, Dawei Microorganism had no operational business and was planned for deregistration[146]

迈克生物股份有限公司 2024 年度董事、监事、高级管理人员薪酬与考核方案 第一章 总则 第一条 为了更好地调动迈克生物股份有限公司（以下简称"公司"）董事、监事、高级管理 人员的工作积极性，建立与现代企业制度相适应的激励约束机制，保持核心管理团队的稳定性， 提升公司的经营管理效益和效率，依据《公司法》《上市公司治理准则》《公司章程》等规定，结 合公司经营规模、业绩等实际情况，参考行业特点，特制订本方案。 第二条 本方案适用于公司董事、监事及高级管理人员。 第三条 本方案所称董事，是指本方案执行期间公司董事会的全部在职成员，包括内部董事、 外部董事及独立董事。 本方案所称监事，是指方案执行期间公司监事会的全部在职成员，包括内部监事和外部监事。 内部监事，是指与公司之间签订聘任合同或劳动合同的公司员工或公司管理人员兼任的监事（包 括职工监事）。外部监事，指不在公司担任除监事外的其他职务的监事。 本方案所称高级管理人员，是指总经理、财务总监、研发总监、市场运营总监、商务总监、 生产总监、行政总监、战略投资总监、董事会秘书等高级管理人员。 第四条 2024 年董事、监事及高级管理人员的薪酬方案以公司经济效益为出发点 ...

我们接受委托，审核了后附的迈克生物股份有限公司 (以下简称 "迈克生物") 董事会就 2023 年 12 月 31 日迈克生物财务报告内部控制 有效性作出的认定执行了鉴证。 一、董事会对内部控制的责任 迈克生物股份有限公司 内部控制鉴证报告 二〇二三年度 内部控制鉴证报告 信会师报字[2024]第 ZD10091 号 迈克生物股份有限公司全体股东： 迈克生物董事会的责任是按照《企业内部控制基本规范》的相关 规定建立健全和有效实施内部控制，评价其有效性，并如实披露内部 控制评价报告。 二、注册会计师的责任 我们的责任是在实施鉴证工作的基础上对财务报告内部控制的 有效性发表鉴证结论。 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第 3101 号——历 史财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证业务。该 准则要求我们遵守中国注册会计师职业道德规范，计划和实施鉴证工 作，以对迈克生物是否于 2023 年 12 月 31 日在所有重大方面按照《企 业内部控制基本规范》的相关规定保持有效的财务报告内部控制获取 合理保证。在执行鉴证工作过程中，我们实施了包括了解、测试和评 价内部控制的有效性以及我们认为 ...

作为迈克生物股份有限公司（以下简称"公司"）第四届、第五届董事会独立董事，2023 年度， 本人严格按照《公司法》《证券法》等法律、法规、规范性文件和《公司章程》《独立董事工作 制度》的相关规定，诚信、勤勉、尽责、忠实地履行职责，积极出席相关会议，对各项议案进行 认真审议，对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会委员的作用。 一方面，严格审核公司提交董事会的相关事项，维护公司和股东的合法权益，促进公司规范运作； 另一方面发挥自身的专业优势，积极关注和参与研究公司的发展，为公司的内部控制、薪酬激励 等工作提出了意见和建议。 现就本人 2023 年度履行独立董事职责情况汇报如下： 一、本人基本情况、任职资格及独立性说明 本人，傅代国，1964 年 10 月出生，中国国籍，无境外永久居留权，博士学历。曾任川润股 份有限公司独立董事、利尔化学股份有限公司独立董事、北方君正集成电路股份有限公司独立董 事，现任西南财经大学西部商学院院长、会计学教授、博士生导师，通威股份有限公司独立董事、 四川郎酒股份有限公司独立董事。本人自 2019 年 1 月 22 日起担任公司独立董事。 本人具备上市公司独立董 ...

迈克生物股份有限公司 2023 年度 法定代表人：唐勇 主管会计工作负责人：尹珊 会计机构负责人（会计主管人员）：游平 汇总表 第 1 页 非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的关联 | 上市公司核算 | 年期初占 2023 | 年度占用累计发 2023 | 年度占用资 2023 | 年度偿还 2023 | 年期末 2023 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | 的会计科目 | 用资金余额 | 生金额（不含利息） | 金的利息(如有) | 累计发生金额 | 占用资金余额 | 原因 | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | - | - | | | 前控股股东、实际控 | | | | | | | | | | | | ...

证券代码:300463 证券简称:迈克生物 公告编号:2024-039 迈克生物股份有限公司 关于变更会计政策的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）根据中华人民共和国财政部（以下简称"财 政部"）颁布的《企业会计准则解释第17号》变更相应的会计政策。公司本次会计政策变更事 项属于根据法律法规或者国家统一的会计制度要求的会计政策变更，该事项无需提交公司董 事会、股东大会审议，不会对公司财务状况、经营成果和现金流量产生重大影响。具体情况 如下： 一、本次变更会计政策的概述 （一）变更原因 2023年10月25日，财政部发布了《关于印发<企业会计准则解释第17号>的通知》（财会 〔2023〕21号）（以下简称"准则解释第17号"），根据财政部要求，"关于流动负债与非流动负 债的划分"、"关于供应商融资安排的披露"和"关于售后租回交易的会计处理"内容自2024 年1月1日起施行。基于上述会计准则解释，公司需对会计政策进行相应变更，并按以上文件 规定的起始日开始执行上述会计准则。 （二）变更前采用的会计政策 本次会 ...

迈克生物股份有限公司 审计报告及财务报表 二〇二三年度 迈克生物股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-90 | 审计报告 信会师报字[2024]第 ZD10090 号 迈克生物股份有限公司全体股东： 一、 审计意见 我们审计了迈克生物股份有限公司（以下简称迈克生物）财务报 表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度 的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所 有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公允反映了迈克生物 ...

证券代码：300463 证券简称：迈克生物 公告编号：2024-033 迈克生物股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、董事会会议召开情况 1、迈克生物股份有限公司（以下简称"公司"）第五届董事会第十四次会议通知于 2024 年 4 月 14 日以邮件、短信、电话的方式向全体董事发出并送达。 2、本次会议于 2024 年 4 月 24 日在公司会议室以现场和通讯相结合的方式召开。 3、本次会议应出席会议的董事 9 人，实际出席会议的董事 9 人。 4、会议由董事长唐勇先生召集并主持，公司监事、部分高级管理人员、持续督导券商列 席了会议。 5、本次会议的召集、召开及表决程序符合《中华人民共和国公司法》（以下简称"《公司 法》"）等法律、法规、规范性文件以及《迈克生物股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，会议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，本次会议以现场书面表决方式通过以下议案： （一）审议通过《关于公司 2023 年度总经理工作报告的议案》 表决结果：9 票 ...